Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
RESEARCH TOOLSreports
Holding HRMY?
Track your performance easily
HRMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.14 - $41.61
Previous CloseN/A
Volume87.33K
Average Volume (3M)547.41K
Market Cap
$2.20B
Enterprise Value$2.14B
Total Cash (Recent Filing)$83.52M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)18.2
Beta1.37
Next Earnings
Feb 19, 2025EPS Estimate
0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.11
Shares Outstanding57,031,296
10 Day Avg. Volume513,898
30 Day Avg. Volume547,411
Standard Deviation0.13
R-Squared0.08
Alpha-0.00110
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.09
Price to Cash Flow (P/CF)7.50
P/FCF Ratio7.10
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue3.14
Enterprise Value/Gross Profit4.64
Enterprise Value/Ebitda12.76
Forecast
1Y Price Target
$50.57Price Target Upside31.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Harmony Biosciences Holdings News
PremiumCompany Announcements
Harmony Biosciences Projects Strong Revenue Growth for 2025
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHRMY reported a top- and bottom-line beat with Wakix net revenue surpassing consensus estimates.
Pipeline PotentialThe company's pipeline includes assets across sleep/wake, neurobehavioral, and epilepsy franchises, which are seen as robust and promising.
Product LaunchStrong commercial launch of WAKIX expected to continue, with label to expand to larger market in IH in 2025.
Bears Say
Clinical Development RiskRisks include clinical development risk tied to pitolisant GR, pitolisant HD, ZYN002, and EPX100, among others.
Orexin Program DetailsThe market may have been disappointed by the lack of details on the orexin program at the Investor Day, which led to a decline in HRMY shares.
Stock PerformanceThe announcement of a secondary offering by HRMY's founding investors has caused a setback in the stock's performance.
---
Ownership Overview
26.73% Insiders
18.34% Mutual Funds
0.17% Other Institutional Investors
29.41% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HRMY FAQ
What was Harmony Biosciences Holdings’s price range in the past 12 months?
Harmony Biosciences Holdings lowest stock price was $28.14 and its highest was $41.61 in the past 12 months.
What is Harmony Biosciences Holdings’s market cap?
Harmony Biosciences Holdings’s market cap is $2.20B.
When is Harmony Biosciences Holdings’s upcoming earnings report date?
Harmony Biosciences Holdings’s upcoming earnings report date is Feb 19, 2025 which is in 32 days.
How were Harmony Biosciences Holdings’s earnings last quarter?
Harmony Biosciences Holdings released its earnings results on Oct 29, 2024. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.665 by $0.125.
Is Harmony Biosciences Holdings overvalued?
According to Wall Street analysts Harmony Biosciences Holdings’s price is currently Undervalued.
Does Harmony Biosciences Holdings pay dividends?
Harmony Biosciences Holdings does not currently pay dividends.
What is Harmony Biosciences Holdings’s EPS estimate?
Harmony Biosciences Holdings’s EPS estimate is 0.72.
How many shares outstanding does Harmony Biosciences Holdings have?
Harmony Biosciences Holdings has 57,031,296 shares outstanding.
What happened to Harmony Biosciences Holdings’s price movement after its last earnings report?
Harmony Biosciences Holdings reported an EPS of $0.79 in its last earnings report, beating expectations of $0.665. Following the earnings report the stock price went up 16.056%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings?
Among the largest hedge funds holding Harmony Biosciences Holdings’s share is Royce & Associates LLC. It holds Harmony Biosciences Holdings’s shares valued at 3M.
---
Harmony Biosciences Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$50.57 (31.21% Upside)
$50.57 (31.21% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 20.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $278.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.87%
12-Months-Change
Fundamentals
Return on Equity
22.75%
Trailing 12-Months
Asset Growth
19.33%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.
---
HRMY Company Deck
---
HRMY Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with a strong financial performance, robust pipeline, and strategic plans for future growth. Despite increased operating expenses and some long timelines for clinical data, the company maintains a positive trajectory with significant market opportunities.Read More>---
HRMY Stock 12 Month Forecast
Average Price Target
$50.57
▲(31.21% Upside)
Technical Analysis
Axsome Therapeutics
―
BioCryst
―
Revance Therapeutics
―
Intra-Cellular Therapies
―
Minerva Neurosciences
―
Karyopharm Therapeutics
―
Best Analysts Covering HRMY
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+2.92%
reiterated a buy rating last month
Copying David Amsellem's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +2.92% per trade.
---